More recently, using two retrospective cohorts of unselected BC, our team showed that the nuclear expression of PRMT5 is a predictive marker of sensitivity to tamoxifen but was not correlated to the response to aromatase inhibitors [194]. The gene discussed is PRMT5; the disease is breast cancer.